Delayed gastric emptying is most pronounced within the first 3 months of use, and may subside after 20 weeks according to one study.20 Other data on patients undergoing upper endoscopy suggest no predictability regarding the interval of GLP-1 agonists (e.g., semaglutide) discontinuation period and the prevalence of finding retained gastric contents at the time of endoscopy.21 In the setting of diabetes, patients already present with an elevated baseline risk of gastroparesis,22 and it is uncertain how GLP-1 agonists may further affect this risk. This evidence concerns the gene GCG and diabetes mellitus.